RxSight Inc. (RXST) announced that it expects revenue for the fourth quarter 2025 to be approximately $32.6 million. Analysts expect the company to report revenues of $27.53 million for the fourth quarter. Analysts' estimates typically exclude special items.
Preliminary unaudited 2025 fiscal year revenue is expected to be approximately $134.5 million, compared to November guidance of $125 million to $130 million. Analysts expect annual revenue of $129.25 million for the fiscal year 2025.
The company also announced that it appointed Mark Wilterding as Chief Financial Officer, effective January 11, 2026.
Wilterding has more than 25 years of financial leadership experience, most recently serving as the Senior Vice President of Global Finance for Edwards Lifesciences, where he joined in 2019. Prior to joining Edwards Lifesciences, Wilterding worked for Medtronic and spent the first 15 years of his career at Citi and Credit Suisse.
Audited full-year 2025 financial results and full-year 2026 guidance will be announced in conjunction with the company's fourth quarter earnings release in February.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.